Conditions: Acute Schizophrenia Schizoaffective Disorder
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 234
Healthy volunteers: no

Brief summary:
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.

Detailed description:

Arms:
arm 1: RP5063 15 mg once daily arm 2: RP5063 30 mg once daily arm 3: RP5063 50 mg once daily arm 4: Placebo once daily arm 5: aripiprazole 15 mg daily

Interventions: intervention 1: RP5063 intervention 2: placebo intervention 3: aripiprazole
Intervention descriptions: intervention 1: daily intervention 2: daily intervention 3: daily

Protocol document: